Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Class effects and evidence-based medicine.

C D Furberg1

  • 1Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157-1063, USA.

Clinical Cardiology
|July 14, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lipoprotein-associated phospholipase A2 (Lp-PLA2) and future risk of type 2 diabetes: results from the Cardiovascular Health Study.

The Journal of clinical endocrinology and metabolism·2012
Same author

Double-blindness protects scientific validity.

Journal of thrombosis and haemostasis : JTH·2007
Same author

Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel.

Journal of internal medicine·2006
Same author

Drug safety: the different perspectives.

Evidence-based cardiovascular medicine·2005
Same author

Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment.

Lancet (London, England)·2003
Same author

Doxazosin, an inferior antihypertensive agent?

Journal of human hypertension·2002
Same journal

In-Hospital Cardiac Arrest Detection Performance Analysis and Comparison on Effective Feature Selection.

Clinical cardiology·2026
Same journal

Interpreting the Association Between Diuretic Intensity Score and Mortality: The Potential Roles of Diuretic Responsiveness and Mineralocorticoid Receptor Antagonist Therapy.

Clinical cardiology·2026
Same journal

Heart Failure With Preserved Ejection Fraction-Like Phenotype in Coronary Artery Disease and Obstructive Sleep Apnea: Insights From the RICCADSA Cohort.

Clinical cardiology·2026
Same journal

Ethanol Infusion Into the Vein of Marshall for Atrial Fibrillation: Clinical Efficacy and Technical Limitations.

Clinical cardiology·2026
Same journal

Methodological Considerations Regarding Diuretic Intensity Score and Mortality in Hospitalized Heart Failure Patients.

Clinical cardiology·2026
Same journal

Inpatient Outcomes and Complications After Left Atrial Appendage Occlusion in Rural Versus Urban Hospitals in the United States.

Clinical cardiology·2026
See all related articles

Angiotensin-converting enzyme (ACE) inhibitors, while sharing a mechanism, exhibit significant pharmacokinetic and pharmacodynamic variations. These differences impact clinical efficacy, meaning not all ACE inhibitors are interchangeable for patients.

Area of Science:

  • Pharmacology
  • Clinical Therapeutics

Background:

  • Drugs within the same therapeutic class, such as angiotensin-converting enzyme (ACE) inhibitors, can possess distinct pharmacodynamic and pharmacokinetic profiles.
  • Variations in potency, activation requirements, lipophilicity, elimination routes, and half-life exist among ACE inhibitors.

Purpose of the Study:

  • To highlight the potential clinical relevance of inter-drug variability within the ACE inhibitor class.
  • To question the universal applicability of the
  • Main_Methods
  • Main_Results
  • Conclusions

Main Methods:

  • Literature review of clinical trials and pharmacological properties of ACE inhibitors.
  • Analysis of pharmacokinetic and pharmacodynamic data for individual ACE inhibitors.

Related Experiment Videos

Main Results:

  • Significant quantitative differences exist among ACE inhibitors, potentially affecting therapeutic outcomes in specific patient groups.
  • Equipotency in clinical efficacy across different ACE inhibitors is challenging to establish.
  • The concept of a
  • Conclusions

Conclusions:

  • The
  • Untested ACE inhibitors within a class should be regarded as unproven due to significant inter-drug variability.
  • Clinical decisions should consider individual drug properties rather than assuming a universal "class effect".